199 related articles for article (PubMed ID: 32583565)
1. Characterization of T-DM1-resistant breast cancer cells.
Sauveur J; Conilh L; Beaumel S; Chettab K; Jordheim LP; Matera EL; Dumontet C
Pharmacol Res Perspect; 2020 Aug; 8(4):e00617. PubMed ID: 32583565
[TBL] [Abstract][Full Text] [Related]
2. ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer.
Barok M; Le Joncour V; Martins A; Isola J; Salmikangas M; Laakkonen P; Joensuu H
Cancer Lett; 2020 Mar; 473():156-163. PubMed ID: 31904483
[TBL] [Abstract][Full Text] [Related]
3. Combination efficacy of pertuzumab and trastuzumab for trastuzumab emtansine-resistant cells exhibiting attenuated lysosomal trafficking or efflux pumps upregulation.
Yamashita-Kashima Y; Shu S; Osada M; Fujimura T; Yoshiura S; Harada N; Yoshimura Y
Cancer Chemother Pharmacol; 2020 Nov; 86(5):641-654. PubMed ID: 32997196
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer.
Hunter FW; Barker HR; Lipert B; Rothé F; Gebhart G; Piccart-Gebhart MJ; Sotiriou C; Jamieson SMF
Br J Cancer; 2020 Mar; 122(5):603-612. PubMed ID: 31839676
[TBL] [Abstract][Full Text] [Related]
5. YES1 as a Therapeutic Target for HER2-Positive Breast Cancer after Trastuzumab and Trastuzumab-Emtansine (T-DM1) Resistance Development.
Fujihara M; Shien T; Shien K; Suzawa K; Takeda T; Zhu Y; Mamori T; Otani Y; Yoshioka R; Uno M; Suzuki Y; Abe Y; Hatono M; Tsukioki T; Takahashi Y; Kochi M; Iwamoto T; Taira N; Doihara H; Toyooka S
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884609
[TBL] [Abstract][Full Text] [Related]
6. Trastuzumab emtansine (T-DM1) as adjuvant treatment of HER2-positive early breast cancer: safety and efficacy.
Molinelli C; Parisi F; Razeti MG; Arecco L; Cosso M; Fregatti P; Del Mastro L; Poggio F; Lambertini M
Expert Rev Anticancer Ther; 2021 Mar; 21(3):241-250. PubMed ID: 33245671
[No Abstract] [Full Text] [Related]
7. Molecular targeting of HER2-overexpressing biliary tract cancer cells with trastuzumab emtansine, an antibody-cytotoxic drug conjugate.
Yamashita-Kashima Y; Yoshimura Y; Fujimura T; Shu S; Yanagisawa M; Yorozu K; Furugaki K; Higuchi R; Shoda J; Harada N
Cancer Chemother Pharmacol; 2019 Apr; 83(4):659-671. PubMed ID: 30659304
[TBL] [Abstract][Full Text] [Related]
8. Hsp90 inhibition and co-incubation with pertuzumab induce internalization and degradation of trastuzumab: Implications for use of T-DM1.
Skeie M; Nikolaysen F; Chitano Y; Stang E
J Cell Mol Med; 2020 Sep; 24(17):10258-10262. PubMed ID: 32672902
[TBL] [Abstract][Full Text] [Related]
9. STAT3 activation confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive breast cancer.
Wang L; Wang Q; Gao M; Fu L; Li Y; Quan H; Lou L
Cancer Sci; 2018 Oct; 109(10):3305-3315. PubMed ID: 30076657
[TBL] [Abstract][Full Text] [Related]
10. Cell proliferation and invasion are regulated differently by EGFR and MRP1 in T-DM1-resistant breast cancer cells.
Endo Y; Lyon S; Shen Y; Mohan N; Wu WJ
Sci Rep; 2019 Nov; 9(1):16383. PubMed ID: 31704984
[TBL] [Abstract][Full Text] [Related]
11. Trastuzumab emtansine: mechanisms of action and drug resistance.
Barok M; Joensuu H; Isola J
Breast Cancer Res; 2014 Mar; 16(2):209. PubMed ID: 24887180
[TBL] [Abstract][Full Text] [Related]
12. A Novel Anti-HER2 Antibody-Drug Conjugate XMT-1522 for HER2-Positive Breast and Gastric Cancers Resistant to Trastuzumab Emtansine.
Le Joncour V; Martins A; Puhka M; Isola J; Salmikangas M; Laakkonen P; Joensuu H; Barok M
Mol Cancer Ther; 2019 Oct; 18(10):1721-1730. PubMed ID: 31292166
[TBL] [Abstract][Full Text] [Related]
13. Acquired resistance to trastuzumab/pertuzumab or to T-DM1 in vivo can be overcome by HER2 kinase inhibition with TAS0728.
Irie H; Kawabata R; Fujioka Y; Nakagawa F; Itadani H; Nagase H; Ito K; Uchida J; Ohkubo S; Matsuo K
Cancer Sci; 2020 Jun; 111(6):2123-2131. PubMed ID: 32248641
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer Cells.
Li G; Guo J; Shen BQ; Yadav DB; Sliwkowski MX; Crocker LM; Lacap JA; Phillips GDL
Mol Cancer Ther; 2018 Jul; 17(7):1441-1453. PubMed ID: 29695635
[TBL] [Abstract][Full Text] [Related]
15. Targeting TACC3 Induces Immunogenic Cell Death and Enhances T-DM1 Response in HER2-Positive Breast Cancer.
Gedik ME; Saatci O; Oberholtzer N; Uner M; Akbulut Caliskan O; Cetin M; Aras M; Ibis K; Caliskan B; Banoglu E; Wiemann S; Üner A; Aksoy S; Mehrotra S; Sahin O
Cancer Res; 2024 May; 84(9):1475-1490. PubMed ID: 38319231
[TBL] [Abstract][Full Text] [Related]
16. Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo.
Barok M; Tanner M; Köninki K; Isola J
Breast Cancer Res; 2011 Apr; 13(2):R46. PubMed ID: 21510863
[TBL] [Abstract][Full Text] [Related]
17. HER2-Overexpressing/Amplified Breast Cancer as a Testing Ground for Antibody-Drug Conjugate Drug Development in Solid Tumors.
Pegram MD; Miles D; Tsui CK; Zong Y
Clin Cancer Res; 2020 Feb; 26(4):775-786. PubMed ID: 31582515
[TBL] [Abstract][Full Text] [Related]
18. Aberrant intracellular metabolism of T-DM1 confers T-DM1 resistance in human epidermal growth factor receptor 2-positive gastric cancer cells.
Wang H; Wang W; Xu Y; Yang Y; Chen X; Quan H; Lou L
Cancer Sci; 2017 Jul; 108(7):1458-1468. PubMed ID: 28388007
[TBL] [Abstract][Full Text] [Related]
19. Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab.
Al Rabadi LS; Cook MM; Kaempf AJ; Saraceni MM; Savin MA; Mitri ZI
BMC Cancer; 2021 Oct; 21(1):1150. PubMed ID: 34706686
[TBL] [Abstract][Full Text] [Related]
20. Neutralization of BCL-2/X
Zoeller JJ; Vagodny A; Taneja K; Tan BY; O'Brien N; Slamon DJ; Sampath D; Leverson JD; Bronson RT; Dillon DA; Brugge JS
Mol Cancer Ther; 2019 Jun; 18(6):1115-1126. PubMed ID: 30962322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
